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The glucocorticoid receptor (GR) affects the transcription of genes
involved in diverse processes, including energy metabolism and the
immune response, through DNA-binding dependent and indepen-
dent mechanisms. The DNA-binding dependent mechanism occurs by
direct binding of GR to glucocorticoid response elements (GREs) at
regulatory regions of target genes. The DNA-binding independent
mechanism involves binding of GR to transcription factors and coac-
tivators that, in turn, contact DNA. A small molecule that competes
with GR for binding to GREs could be expected to affect the DNA-
dependent pathway selectively by interfering with the protein-DNA
interface. We show that a DNA-binding polyamide that targets the
consensus GRE sequence binds the glucocorticoid-induced zipper
(GILZ) GRE, inhibits expression of GILZ and several other known GR
target genes, and reduces GR occupancy at the GILZ promoter.
Genome-wide expression analysis of the effects of this polyamide on
a set of glucocorticoid-induced and -repressed genes could help to
elucidate the mechanism of GR regulation for these genes.
gene regulation  glucocorticoid response element  nuclear receptor 
protein-DNA interface  Py-Im polyamide
The glucocorticoid receptor (GR) is a member of the ligand-activated nuclear receptor group of transcription factors that
bind with high affinity to glucocorticoids (GCs) such as cortisol and
dexamethasone. GR is structurally similar to the androgen and
progesterone receptors, containing a zinc-finger motif DNA-
binding domain, a dimerization domain, and a ligand-binding
domain (1). Ligand binding releases GR from sequestration by
cytoplasmic heat shock proteins (2) and activates a series of cellular
activities that lead to nuclear localization and homodimerization.
Like other steroid hormone receptors, GR is known to modulate
gene transcription via the binding of receptor dimers to specific
palindromic sequences called glucocorticoid response elements
(GREs), usually located in the cis-regulatory region of target
genes—a mode of action termed transactivation. Additionally, the
GR has been shown to exert its actions through an indirect
non–DNA-binding mechanism, termed transrepression, in which
transcriptional modulation is achieved through cross-talk between
GR and other transcription factors such as NF-B (3), activator
protein-1 (AP-1) (4, 5), Sma and Mad-related protein, and mem-
bers of the STAT family (6). This protein-protein cross-talk does
not require the DNA-binding activity of the GR, because GR
mutants that are deficient in dimerization function have been shown
to lose DNA-binding ability as well as simple GRE-mediated
transcription function but retain their transrepression activity (4, 7).
Because many GR target genes are immune modulators, syn-
thetic GR agonists such as dexamethasone are among the most
effective anti-inflammatory drugs available for the treatment of a
variety of chronic and acute inflammatory diseases. Unfortunately,
because of the functions of other GR target genes, long-term
treatment with corticosteroids results in metabolic and behavioral
derangements that can be treatment limiting. Although the GR
targets involved in inflammatory and immune regulation have not
been comprehensively defined, there is a great deal of evidence
suggesting that transrepression—GR interaction with NF-B
and/or AP-1 and the subsequent suppression of their target
genes—is themajor mechanism by whichGCs achieve their desired
anti-inflammatory effect (5, 8, 9).
An understanding of the mechanisms of GR activity on target
genes has been explored using a variety of approaches, including
microarray analysis (10, 11); ChIP scanning (12); andmodulation of
GR activity using siRNA (13), geneticmutants (4), and ligands with
modified structures (14). However, these methods would not be
expected to differentiate explicitly between the direct and indirect
DNA-binding mechanisms of GR action. A small molecule that
competes with GR for binding to the consensus GRE could be
expected to disrupt GR-DNA binding specifically and be used as a
tool to identify GR target genes whose regulation mechanism
depends on a direct protein-DNA interface. This differentiation of
mechanisms of GR target gene regulation could contribute to
efforts to develop more specific GR modulators that retain immu-
nosuppressant functions while minimizing side effects resulting
from other GR targets (15).
N-methylpyrrole (Py)–N-methylimidazole (Im) polyamides are a
class of programmable DNA-binding ligands capable of binding
sequence specifically to DNA with affinities and specificities com-
parable to those of natural DNA-binding proteins (16, 17). As
oligomers composed of Im and Py heterocyclic rings, Py-Im poly-
amides achieve sequence specificity via side-by-side pairings of the
heterocyclic amino acids in the minor groove of DNA: Im paired
against Py distinguishes GC from CG, and Py paired against Py
binds both AT and TA (18, 19). Py-Im polyamides have previously
been used to modulate gene expression in cell culture via inhibition
of the transcription factor-DNA interface of both hypoxia inducible
factor (20, 21) and androgen receptor (22) to their respective DNA
response elements. Interruption of the GR-DNA–binding interac-
tion by polyamides represents an opportunity to regulate a distinct
subset of the known binding sites for the protein. Because Py-Im
polyamides can be selectively programmed to recognize the known
DNA-binding sequence of theGR, there is a unique opportunity to
inhibit the DNA-binding dependent activity of endogenous GR
while leaving the protein-protein–mediated activity unaffected
(Fig. 1).
In this study, we designed a polyamide targeted to the sequence
5-WGWWCW-3 (whereW represents either a TAor anATbase
pair) found in the consensus GRE, with the goal of disrupting
GR-GRE binding (Fig. 2A, polyamide 1). This polyamide binds the
2 known GREs found in the promoter of the well-characterized
GC-induced leucine zipper (GILZ) gene, inhibits expression of
GILZ and 17% of transcripts induced by dexamethasone in cul-
tured alveolar epithelial cells (A549), and reduces GR occupancy
at theGILZ promoter in vivo.A ‘‘mismatch’’ polyamide that targets
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the sequence 5-WGWCGW-3 (Fig. 2A, polyamide 2) is used as a
control for non–GRE-binding polyamide effects. The subset of
GR-regulated genes uniquely affected by the GRE-targeted poly-
amide may represent a set of genes regulated by GR through direct
GR-GRE binding.
Results
Binding Affinities of Py-Im Polyamides to GRE1 and GRE2 of the GILZ
Promoter. The proximal GILZ promoter contains 2 functional
GREs (12) (GRE1: 5-CCTGCActtTGTTCT-3 and GRE2: 5-
AAACAccgTGTTCA-3) spaced 22 bp apart2,500 bp upstream
of the transcription start site (Fig. 2 B and C). The DNA-binding
affinity of polyamides 1 and 2 on this sequence was measured by
quantitativeDNase I footprint titrations using a 5 32P-labeled PCR
fragment of pGRGILZ, which contains a 78-bp sequence from the
promoter encompassing both functional GILZ GREs (Fig. 3A).
Polyamide 1 has Ka  1.9  0.8  1010 M1 for the GRE1
consensus half-site 5-TGTTCT-3 and Ka  8.8  1.8  109 M1
for the GRE2 consensus half-site 5-TGTTCA-3. Binding of
polyamide 2, which targets the sequence 5-WGWCGW-3, to the
GREs is notmeasurable by thesemethods (Ka 1 107M1) (Fig.
3B). Binding of polyamide 2 with Ka  6.3  0.4  109 M1 is
observed at the site 5-TGTCTT-3 located between the GREs.
This is a single base pair mismatch site for polyamide 2; thus,
polyamide 2 can be expected to demonstrate some binding to this
site (16).
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Fig. 1. Effect of polyamide-DNA binding on the 2 major modes of gene
regulation demonstrated by the GR. (Top) Direct mechanism is dependent on
GR-DNA binding at the GRE. (Bottom) Indirect mechanism is dependent on GR
binding to another protein, indicated here as a general transcription factor (TF)
[with binding site TF response element (TFRE)]. A sequence-specific polyamide
designed to bind to the GRE but not to the TFRE would alter gene expression
controlled by the DNA-binding dependent mechanism but not by the DNA-
binding independent mechanism.
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Fig. 2. Polyamide design and GILZ promoter structure. (A) Structure of match
polyamide1designed tobind5-WGWWCW-3andmismatch control polyamide
2designedtobind5-WGWCGW-3,whereWrepresentsaTAoranATbasepair.
Ball-and-stick models of polyamides represent the structure shown, and imida-
zole and pyrrole monomer units are represented by filled and open circles,
respectively. The isophthalic acid tail moiety is represented by a hexagon. (B)
Representation of the GILZ promoter region with its 2 functional GRE sites
indicated. (C) Sequences of the 2GILZGREs shownwith polyamide 1 bound to its
target site.
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Fig. 3. DNAse I footprinting of GILZ promoter region. (A) Sequence of the
pGRGILZ plasmid insert. (B) Storage phosphor autoradiograms from quantita-
tive DNase I footprint titrations of polyamides 1 and 2. Lane 1, intact DNA; lane
2, G reaction; lane 3, A reaction; lane 4, DNase control; lanes 5–13, DNase I
digestion products in the presence of 1, 3, 10, 30, 100, or 300 pM or 1, 3, 10, 30,
or 100 nM polyamide, respectively.
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EMSA. The effects of polyamides 1 and 2 on the binding of
recombinant human GR to an oligo containing the GRE1 site of
the GILZ promoter were measured by EMSA (Fig. 4). Incubation
of the 32P-labeled GRE DNA with recombinant human GR
produces a gel shift that is reduced in the presence of polyamide 1
at concentrations as low as 10 nM. Polyamide 2 has minimal effect
at the same concentrations. The shift is abolished by incubationwith
a 100-fold excess of unlabeled GRE DNA but is unaffected by
similar treatment with a scrambled control DNA, indicating a
specific shift resulting from a GR-GRE–binding event.
Inhibition of GC-Induced GILZ Expression. Induction ofGILZmRNA
by dexamethasone in the presence of polyamides 1 and 2 in A549
cells was measured by quantitative real-time RT-PCR. Polyamide
1 inhibits the expression of dexamethasone-induced GILZ mRNA
up to 65% at 5 and 10 M, as measured in this assay (Fig. 5A).
Polyamide 2 does not show ameasurable effect onGILZ expression
at these concentrations. The GR antagonist mifepristone was used
as a control and inhibits the expression ofGILZ up to 79%at 3M.
GR occupancy at the GILZ promoter was assessed by chromatin
immunoprecipitation (Fig. 5B). A 6-h dexamethasone treatment
results in a 15-fold increase in GR occupancy at the GILZ pro-
moter; treatment of the cells with polyamide 1 for 48 h before
harvest reduces this occupancy, whereas treatment with the mis-
match polyamide 2 shows a more modest effect. Although poly-
amide 2 does not bind the GRE sites, we cannot exclude the
possibility that it may bind to other regions of theGILZ promoter.
Although polyamide 2 affects GILZ promoter occupancy, albeit
significantly less so than polyamide 1, it is somewhat surprising that
polyamide 2 only minimally affects GILZ mRNA. It is not known
what degree of occupancy is necessary for maximal induction of
GILZ under these conditions, however. Treatment of cells by both
polyamides 1 and 2 modestly affects cell proliferation and viability
in a concentration- and time-dependent manner (Fig. S2).
Genome-Wide Microarray Analysis. Global effects of polyamides 1
and 2 and the GR antagonist mifepristone on gene expression in
dexamethasone-stimulated A549 cells were monitored with Af-
fymetrix high-density Human Genome U133 Plus 2.0 arrays, which
interrogate 50,000 transcripts. Of these transcripts, 431 were
affected greater than 2-fold by dexamethasone compared with
noninduced control, with 323 transcripts induced and 108 re-
pressed. An agglomerative clustering analysis of the transcripts
affected by dexamethasone demonstrates distinctive patterns of
genes that are GC-responsive and GR-mediated but have a differ-
ential response to treatment by polyamides 1 and 2 (Fig. 6A) at a
concentration of 5 M. The GR antagonist mifepristone abolishes
the activity of GR, and therefore was used as a control to identify
those transcripts that were affected by a GR-related mechanism.
Four hundred thirty-one transcripts were either induced or re-
pressed by 2-fold or greater (P  0.01) by dexamethasone treat-
ment. Among these, the effects of dexamethasone were abolished
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Fig. 4. Storage phosphor autoradiogram from EMSA of recombinant human
GR binding to a 27-bp oligonucleotide duplex containing the GILZ GRE1. Lanes
represent the following conditions,where * represents 32P labeling: 1, free *GRE
DNA; 2, *GRE DNA	 GR; 3, *GRE DNA	 GR	 GRE DNA; 4, *GRE DNA	 GR	
scrambled DNA; and 5–18, *GRE DNA 	 GR 	 polyamide 1 (lanes 5–11) or
polyamide2 (lanes 12–18) in concentrations increasing from10–100pM; 1, 10, or
100 nM; and 1–10 M, respectively. For full gel, including nonshifted free DNA
bands, see Fig. S1.
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Fig. 5. Inhibition of dexamethasone (dex)-induced GILZ expression by poly-
amides1and2. (A) InductionofGILZmRNAin thepresenceofmifepristone (mif),
polyamide 1, and polyamide 2 as measured by quantitative real-time PCR. Poly-
amide 1 inhibits expression of GILZmRNA up to 65% at 5 and 10 M, whereas
polyamide 2 shows no effect. A 3-Mmif control inhibits expression up to 79%.
Error bars represent SD. (B) Chromatin immunoprecipitation assays with anti-GR
ormockantibodytreatmentexpressedas foldenrichment (specific/mock)ofDNA
sequences at theGILZpromoter.GRoccupancyat theGILZpromoter is decreased
in the presence of polyamide 1 (10 M) and to a lesser extent by polyamide 2.
Error bars represent SD.
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Fig. 6. Global effects on genes interrogated by using Affymetrix high-density
HumanGenomeU133 Plus 2.0 arrays. (A) Agglomerative clustering of transcripts
induced or repressed by dexamethasone (dex) by at least 2-fold under the 4
specified conditions: no treatment control, mifepristone (mif, 3 M), polyamide
1 (5 M), and polyamide 2 (5 M). Clustering was based on an error-weighted
Euclidean correlation of intensity ratios for each treatment as compared with
dex-induced controls. (B) Venn diagram representing genes affected ( fold
change 2.0, P  0.01) by dex and mif. (C) Venn diagram representing genes
affected ( fold change  2.0, P  0.01) by dex and mif as well as by dex and
polyamide 1. Numbers inside the intersections represent genes affected by both
treatments.
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by simultaneous treatment with 3 M mifepristone for 252 tran-
scripts, indicating that these 252 were a result of GR activity (Fig.
6B). For 76 transcripts of this set of 252, the effects of dexameth-
asone treatment were abolished by polyamide 1 to a greater extent
than by polyamide 2, indicating a sequence-specific polyamide
effect on those transcripts (Fig. 6C). This set of 76 transcripts
corresponds to 67 genes, listed in Table 1.We would anticipate that
the regulation of these genes by GR involves a direct GR-GRE
interaction. To analyze the potential GRE sequence-specific role of
polyamide treatment within the subset of GR-regulated genes,
those genes that showed a similar effect fromboth polyamides 1 and
2 were considered to have non–GRE-specific effects and were not
included among those analyzed.Many of the genes identified by the
microarray as dexamethasone responsive are consistent with those
previously identified in this cell line (15). A list of the effect of all
treatment conditions on the GR-regulated genes is available in
Table S1.
Discussion
A mechanistic understanding of cell signaling is fundamental to
the development of improvedmedicines and diagnostics. Toward
this end, the functions of individual biomolecules and their
involved pathways have been explored using both biological and
chemical methods. Genetic approaches include gene knockouts,
dominant negative proteins, and siRNA to affect the activity of
selected genes. Chemical approaches have used preexisting,
designed, or discovered small molecules that perturb a particular
protein or specific protein-protein interaction and have been
used successfully to characterize cell signaling pathways (23–25).
The elucidation of transcription factor, coactivator, and core-
pressor activation; their gene targets; and their mechanisms of
activity is a focus of intense research interest. Genome-wide
high-throughput approaches, including mRNAmicroarray analysis
(26), ChIP-chip (27–29), and (more recently) ChIP-sequencing
(30), have been used to define the targets of transcription factors.
Specific protein-DNA interactions are the interfaces where infor-
mation from protein signaling is converted into programs of gene
expression. Used in the context of genome-wide analysis, small
molecules that perturb this interface in a predictable manner could
become useful tools for understanding gene expression. Program-
mable DNA-binding Py-Im polyamides offer a chemical approach
to perturbing protein-DNA interactions that could be used for
characterization of transcription factor-DNA interactions.We have
reported previously that Py-Im polyamide 1, which targets 5-
WGWWCW-3, inhibits androgen receptor binding to its consensus
sequence 5-GGTACAnnnTGTTCT-3 (22). As members of the
same class of transcription factors, androgen receptor andGRshare
highly conserved DNA-binding domains, similar consensus se-
quences, and a transactivation mode of action. However, each acts
within its individual biological context and responds to distinct
chemical stimuli. The use of polyamide 1 in the context of disrupting
the GR-GRE interface offers additional perspective in the mech-
anistic study of GR gene regulatory action and its dual transacti-
vation/transrepression mechanisms. Because of the central role of
GR in multiple inflammatory response pathways and its role as a
drug target, mechanistic studies of GR-modulated gene expression
are a growing field of study. However, the multiple mechanisms by
which GR mediates gene expression makes identification of GR
target genes a challenge (6, 15, 31). The complex transcriptional
activity of the GR involves DNA-binding dependent as well as
DNA-binding independent mechanisms that result in both gene
activation and gene repression. In general, the most well-
understoodmechanism is that bywhich genes are activated by direct
DNA binding of GR to a GRE in the regulatory region of target
genes, followed by recruitment of coactivators and the general
transcriptionalmachinery.Anotherwell-documented, although less
understood, mechanism is the transrepressionmechanism, in which
GR exerts its influence indirectly by binding to other proteins and
transcription factors, leading to the repression of genes controlled
by those proteins. Intriguingly, an increasing body of evidence
indicates that much of the anti-inflammatory activity of GCs is
mediated by the transrepressionmechanism, a finding that has been
attributed largely to the repression of key inflammatory transcrip-
tion factors, including AP-1 and NF-B (3–5). Meanwhile, many of
the reported side effects of GC treatment have been attributed to
a transactivation mechanism (32). Efforts to develop GC-based
drugs that can dissociate anti-inflammatory and immunosuppres-
sive effects from side effects have focused largely on establishing a
method of dissociating the transrepression activity from the trans-
activation activity of the GR. Much of the work in this area has
centered about the development of uniqueGR-binding ligands that
display a more selective gene-regulation pattern than classical GCs.
The end result of this body of effort has demonstrated that the
problem is complex, because slight alterations in ligand structure
Table 1. Genes affected >2-fold by dexamethasone and mifepristone whose activity is modulated by polyamide 1 and not by
polyamide 2*
Gene
Fold
induction Gene
Fold
induction Gene
Fold
induction Gene
Fold
repression
CDKN1C (N33167) 20 IGFBP1 (NM000596) 4 49111at (N80935) 3 NR4A2 (NM006186) 6
FKBP5 (NM004117) 14 CDC42EP3 (AI754416) 4 TIPARP (AL556438) 3 IER2 (NM004907) 3
DNAJC15 (NM013238) 14 PLEKHA7 (AA758861) 4 EPB41L4A (AU144565) 3 EREG (NM001432) 3
FGD4 (AI949549) 11 CEP3 (AI801777) 4 CEBPD (NM005195) 3 IER3 (NM003897) 3
CIDEC (NM022094) 8 LOC153346 (AU157049) 4 EMP1 (NM001423) 3 NR0B1 (NM000475) 3
EDN3 (NM000114) 8 IL6R (NM000565) 4 LOC54492 (AK026748) 3 MAFK (BG231691) 3
PTGER4 (AA897516) 8 ARRB1 (BE207758) 4 ARRB1 (BC003636) 3 CYP24A1 (NM000782) 3
METTL7A (NM014033) 7 CDC42EP3 (AL136842) 4 SOCS1 (AB005043) 3 EDN1 (NM001955) 2
FAM105A (NM019018) 7 AKAP13 (NM006738) 3 SCNN1G (AI985987) 3 NEIL3 (NM018248) 2
ATAD4 (NM024320) 6 244650at (AA581439) 3 EPB41L4B (NM019114) 3 PTGS2 (AY151286) 2
GOLSYN (NM017786) 6 PKP2 (NM004572) 3 ARRB1 (NM004041) 3 RND1 (U69563) 2
CORO2A (AL515381) 5 FBXL16 (AI613010) 3 IL6R (NM000565) 3
TFCP2L1 (NM014553) 5 CEBPD (AV655640) 3 MT1F (BF246115) 2
RASSF4 (N49935) 5 FOXO3 (AV725666) 3 JPH2 (AA716165) 2
CDH16 (NM004062) 4 FLVCR2 (NM017791) 3 SLC22A5 (NM003060) 2
ACSL1 (NM021122) 4 MT2A (NM005953) 3 RHOU (AL096776) 2
MT1X (NM002450) 4 KIAA0146 (AI363213) 3 MAN1C1 (NM020379) 2
AKAP13 (NM006738) 4 43511sat (AI201594) 3 KIAA0232 (D86985) 2
ACSL1 (NM001995 4 ETNK2 (NM018208 3
*These genes may represent glucocorticoid-responsive genes that are controlled via direct GR-binding mechanisms.
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and chemical reactivity can have a pronounced influence on the
transcriptional regulatory activity of GR (14).
An additional complication tomechanistic study of theGR is the
fact that examples have been noted in which genes are repressed
through DNA-binding dependent GR action, in addition to those
in which genes are activated through DNA-binding independent
action. Techniques using immunoprecipitated chromatin fragments
reveal a great deal of useful information about GR target sites but
are not expected to distinguish between sites of direct GR-GRE
interaction and sites of indirect GR-protein-DNA interaction. Our
approach utilizes a DNA-binding polyamide targeting the consen-
sus GRE that would be expected to dissociate the direct DNA-
binding from the indirect DNA-binding independent GR gene
regulatory mechanisms.
In this study, a sequence-specific polyamide targeted toward the
consensus DNA-binding sequence of the GR was tested on a
well-known GC-induced gene, GILZ, to establish its ability to
disrupt GR-DNA binding and thereby regulate gene transcription.
Polyamide 1, designed to target the sequence 5-WGWWCW-3,
has been shown by DNase I footprinting to bind at subnanomolar
concentrations to the right half-site of each of 2 different functional
GREs located in the promoter region of the GILZ gene. Quanti-
tative real-time PCR analysis of RNA isolated from A549 cells
treated with polyamide 1 demonstrates a 60% reduction in dexa-
methasone-induced GILZ mRNA levels as compared with vehicle
control. Chromatin immunoprecipitation indicates that in the pres-
ence of polyamide 1, the dexamethasone-inducedGRoccupancy of
the GILZ promoter is reduced, suggesting that it is polyamide
occupancy at this site that is responsible for the lowered mRNA
expression levels. A control polyamide 2 targeted at a different
sequence, 5-WGWCGW-3, shows a reduced effect on GR pro-
moter occupancy and no effect on GILZ gene transcription.
The established ability of polyamide 1 to disrupt the GR-GRE
interaction for GILZ led us to a genome-wide search for other
transcriptional events that are interrupted sequence specifically.
Affymetrix microarrays interrogating 50,000 transcripts were
chosen to examine the global effect of polyamides 1 and 2 at a
concentration of 5 M on dexamethasone-treated cells. The GR
antagonistmifepristonewas used as a control to isolate which of the
dexamethasone-responsive transcripts result from GR activity.
These conditions isolated 252 genes considered to be genuine
GR-modulated GC-affected transcripts. Both polyamides had a
similar and modest effect on cell proliferation under these exper-
imental conditions.
To tease out which of these effects is attributable to a binding
event at a 5-WGWWCW-3 sequence corresponding to aGRE,we
have eliminated genes from the list that were affected by polyamide
2, because both the footprinting and ChIP data show that it is
possible that this compound may have an effect on genes whose
promoters contain a 5-WGWCGW-3 site. Of the list of 252
GR-modulated transcripts, treatment with polyamide 1 had a
unique effect on 170 transcripts over treatment with polyamide 2.
This left us with a final list of 170 transcripts whose expression is
confidently affected both by GR and our sequence-specific small
molecule.Of this final list of confidently interrogated transcripts, we
find 76 transcripts, corresponding to 67 genes, that are identified as
genes whose expression was modulated by polyamide 1. We believe
this list of genes to represent 67 genes that are regulated by direct
GR-DNA interactions. Although little information exists in the
literature linking GC response with these genes, we note that
several genes with known functional GRE-binding sites are in-
cluded in the list (Table 2). For genes in which the binding site has
been identified, the sequence is listed, with the predicted polyamide
1 target-binding site underlined. The GREs for the genes listed in
this table have been determined to have GC-induced GR occupa-
tion at the indicated location relative to the given gene. For some
of these genes, functionality has been confirmed via point mutation
or a luciferase-driven reporter assay. The fact that these genes
contain polyamide 1 binding sites and demonstrate responsiveness
to polyamide 1 treatment gives us confidence that the subset of
genes identified here represents a previously undescribed list of
DNA-binding dependent genes to be explored by the GR field.
There is still very little known about many of the genes that are
affected by GCs, including which genes are activated as a result of
transrepressedmechanisms or transactivatedmechanisms. The lack
of identified GREs to be found in the literature complicates the
search for genes that are regulated by the transactivation mecha-
nism. DNA-binding polyamides represent a unique approach to
differentiating the transrepression from transactivation activity of
the GR—the potential to selectively block the protein-DNA inter-
actions of endogenous GR while leaving the protein-protein inter-
actions unaffected. This approach is limited by the target site
degeneracy of both the polyamide and GR, effects of specific
polyamide-DNA binding on programs of other transcription fac-
tors, and nonspecific effects of polyamides that are independent of
sequence-specific polyamide-DNA binding. Small molecules that
affect specific GR-protein interactions represent a complementary
approach that is as yet unexplored. It is our hope that the list of
genes provided by this study serves as a guide to genes that
necessitate further exploration in the search to regulate the trans-
activation mechanism of GC response selectively.
Materials and Methods
Unless otherwise stated, DNA oligos were purchased from Integrated DNA
Technologies. Unless otherwise stated, reagents were purchased from Sigma-
Aldrich.
Synthesis of Polyamides. Polyamides 1 and 2 were synthesized by solid-phase
methods on Kaiser oxime resin (Nova Biochem) following established protocols
(33) and were cleaved subsequently from resin with 3,3-diamino-N-methyl-
dipropylamineandpurifiedbyreverse-phaseHPLC. Isophthalicacidwasactivated
with PyBOP (Nova Biochem) and conjugated to the polyamides as previously
described (34). Purities and identities of the polyamides were assessed by HPLC,
UV-visible spectroscopy, and MALDI-TOF MS.
Determination of DNA-Binding Affinity and Sequence Specificity. Plasmid
pGRGILZwas constructedby insertinga78-bp sequence fromtheGILZpromoter
Table 2. Genes identified in our study that have previously been shown to have GR-occupied
and/or functional GREs
Gene GRE (53 3) Location Reference no.
CDKN1C AGAACAgccTGTCCT Promoter 32
FKBP5 AGAACAgggTGTTCT Intron 31, 33
ACSL1 AGCACAtcgAGTTCA Intron 31
AKAP13 — Exon 31
ETNK2 — Intron 31
IGFBP1 — Intron, Upstream 31
MT2A AGGACAgccTGTCCT
AGAACAggaTGTTTA
Upstream 31
IL6R — Intron 31
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containing GRE1 and GRE2 into pUC19 plasmid. Quantitative DNase I footprint
titration experiments were performed following established protocols to mea-
sure the binding affinities of polyamides 1 and 2on a 5–32P-labeled fragment of
pGRGILZ. Detailed experimental protocols are reported elsewhere (35).
EMSA. The oligonucleotide 5-GTATAGCCTGCACTTTGTTCTGTCTAC-3 repre-
senting a 27-bp section of the GILZ promoter containing GRE1 (underlined) was
annealed to its complement and end-labeled with 32P. Aqueous solutions of
polyamides 1 and 2 at the indicated concentrations were incubated with the
duplex at room temperature for 2 h in 5L 5 buffer containing 100mMHepes
(pH 7.9), 300 mM KCl, 25 mM MgCl2, 10 mM DTT, and 50% (vol/vol) glycerol.
Recombinant humanGR (3.5mg/mL; Affinity Bioreagents) was diluted 1:20with
50g/L BSAand stored as a frozen stock solution. Fresh aliquots of this solution
were used for each experiment and discarded after use. Two microliters of the
dilutedGRprotein, 1Lof200ng/LPoly(deoxyinosinic-deoxycytidylic) acid, and
1LofunlabeledDNA(forcontrol lanes)weretakenupinwatertoafinalvolume
of 15 L and incubated at 4 °C for 30 min. This solution was added to the
polyamide-DNA complex and incubated at room temperature for 1 h before
being separated on a 6%polyacrylamide gel in 1 Tris-Borate-EDTABuffer. Gels
were visualized on a phosphorimager.
Measurement of Dexamethasone-Induced mRNA. A549 cells [American Type
Culture Collection (ATCC)] were plated in 24-well plates at a density of 20–25
103 cells per well (40–50 103 cells/mL) in F12-K medium (ATCC) supplemented
with 10% (vol/vol) FBS (Irvine Scientific) and 4mMpenicillin/streptomycin. After
24 h, the medium was replaced with F12-K containing 10% (vol/vol) charcoal-
stripped FBS, penicillin/streptomycin, and polyamides or mifepristone at the
designated concentrations. Cells were grown for an additional 48 h and then
treatedwith 100 nMdexamethasone for 6 h (Fig. S3). Isolation of RNAand cDNA
synthesis were performed as described. Quantitative real-time RT-PCR was per-
formed with SYBR Green PCR Master Mix (Applied Biosystems) following the
manufacturer’s protocol on an ABI 7300 qPCR instrument (Applied Biosystems).
mRNA of the genes of interest was measured relative to -glucuronidase as an
endogenous control. Primer sequencesweredesignedusingPrimer3 (36) andare
available on request.
Measurement of Cell Proliferation andViability.A549cellswereplated in96-well
plates, 100 L at 20  103 cells/mL in F12-K medium containing 10% (vol/vol)
charcoal-strippedFBSand4mMpenicillin/streptomycin.After the indicated time
period,10LofCellProliferationReagentWST-1 (Roche)wasaddedtoeachwell.
Reagent was allowed to incubate at 37 °C for 30 min, and absorbance was read
at 450 nm on a Perkin-Elmer Victor 3 multiwell plate reader.
Chromatin Immunoprecipitation.A549cellswereplated in15-cmdiameterplates
at a density of 10 105 cells per plate. Media conditions, polyamide treatment,
time course, and dexamethasone stimulation were identical to the conditions
described previously for qPCR. On completion of the 6-h dexamethasone treat-
ment, cells were cross-linked by treatment with 1% formaldehyde for 10 min.
Chromatin was isolated using a ChIP-IT kit (Amersham) following the manufac-
turer’s protocol. Chromatin was sheared and immunoprecipitated by overnight
incubation at 4 °C with N499 anti-GR antibody (a gift from Keith Yamamoto,
UniversityofCalifornia, SanFrancisco,CA).A1:1mixtureofProteinGandProtein
AAgarose beads (Upstate) was used to isolate the immunoprecipitatedmaterial
via centrifugation. Cross-links were reversed, and the DNA was isolated via
phenol/chloroform extraction followed by ethanol precipitation. qPCR utilizing
primers targeted to the GILZ promoter was used to assess enrichment of bound
fragments as compared with mock-precipitated (no antibody) controls. PCR
assaysweremonitoredwith SYBRGreenPCRMasterMix (AppliedBiosystems) on
anABI 7300 qPCR instrument. Primer sequences and amore detailed experimen-
tal protocol are available on request.
Analysis of Gene Expression with Oligonucleotide Microarrays. A549 cells were
plated in 12-well plates at a density of 40–50 103 cells per well. Media condi-
tions, polyamide treatment, time course, and dexamethasone stimulation were
identical to the conditions described previously for qPCR and ChIP. Mifepristone
was added at the same time as polyamide was added. RNA was isolated as
previously described. The RNA was submitted to the Millard and Muriel Jacobs
Gene Expression Facility at the California Institute of Technology, where labeled
mRNAwas hybridized to Affymetrix high-density HumanGenomeU133 Plus 2.0
arrays according to established protocols. Gene expression was analyzed using
Resolver (Rosetta Biosoftware). Data were uploaded to the Gene Expression
Omnibus (GEO) repository (accession no. GSE17307).
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